Lymphoma Clinical Trials in Baltimore

Showing 221-240 of 633 trials

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

NCT06116110

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

Non Hodgkin Lymphoma

Miltenyi Biomedicine GmbH150 participantsStarted May 2024

Stanford, California, United States • New Haven, Connecticut, United States • Baltimore, Maryland, United States +2 more locations

RECRUITING34 miles

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

NCT04981795

The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.

Diffuse Large B-cell Lymphoma

Incyte Corporation100 participantsStarted Sep 2021

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Orange, California, United States +22 more locations

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Lymphoma Trials in Other Cities

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Other Conditions in Baltimore